Trials / Enrolling By Invitation
Enrolling By InvitationNCT06844240
Efficacy and Safety of XEN63 Gel Implant
Efficacy and Safety of the XEN63: a Prospective Observational Multicenter Study.
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 96 (estimated)
- Sponsor
- Mario Stirpe · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation.
Detailed description
The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation. Every patients will be followed for 24 months. Secondary aims of the study are: * Evaluating the hypotensive efficacy of the XEN63 12 months after implantation. * Assessing the safety of the XEN63 device after 12 and 24 months after implantation. * Comparing the hypotensive efficacy of the XEN63 in glaucomatous patients undergoing the solo procedure and in those undergoing the combo procedure * Evaluating the quality of life of patients undergoing XEN63 implantation 12 and 24 months after implantation. * Evaluating the association between factors related to the patient, the surgical technique or post-operative management and the hypotensive efficacy of the device during follow-up.
Conditions
Timeline
- Start date
- 2024-11-28
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
- First posted
- 2025-02-25
- Last updated
- 2025-02-25
Locations
19 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06844240. Inclusion in this directory is not an endorsement.